<DOC>
	<DOCNO>NCT00936221</DOCNO>
	<brief_summary>To assess efficacy term overall survival AZD6244 combination dacarbazine , compare dacarbazine alone , first line patient BRAF mutation positive advance cutaneous unknown primary melanoma</brief_summary>
	<brief_title>Comparison AZD6244 Combination With Dacarbazine Versus ( v ) Dacarbazine Alone BRAF Mutation Positive Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histological cytological confirmation advance ( inoperable stage III stage IV ) cutaneous unknown primary melanoma Tumor sample confirm BRAF mutation positive Diagnosis uveal mucosal melanoma Any prior Investigational therapy comprise inhibitor Ras , Raf MEK Having receive investigational drug within 30 day start treatment , recover side effect investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>BRAF mutation positive</keyword>
	<keyword>advanced melanoma</keyword>
	<keyword>Advanced cutaneous melanoma</keyword>
	<keyword>Unknown primary melanoma</keyword>
</DOC>